youtube
Tracking the latest regulatory decisions and pipeline updates within the clinical biotechnology sector? Capricor Therapeutics, Inc. (NASDAQ: CAPR) witnessed a sharp 10% decline in its share price after the Food and Drug Administration (FDA) scheduled an official Advisory Committee (AdCom) meeting for its late-stage muscular dystrophy treatment candidate.
The upcoming expert panel review, set for July 29, will thoroughly evaluate the firm's resubmitted Biologics License Application (BLA) ahead of the critical August 22 prescription drug action date. While the broader sell-side analyst consensus technically maintains a bullish Strong Buy on Capricor, near-term regulatory hurdles have caused notable tension. Over the last month, five institutional research analysts have proactively revised their immediate financial estimates downward. In light of these heightened testing and compliance risks overshadowing the company's clinical pipeline, Seeking Alpha’s automated Quant Rating continues to flash a neutral Hold on Capricor.
|
